ASCENTAGE

Ascentage Pharma Group experienced a surge-and-retreat pattern during the morning session in Hong Kong, opening at 34.70 HKD but quickly declining to close at 32.08 HKD, down 5.09% from the previous close of 33.80 HKD, matching the intraday low; the range between the day's high and low was 2.62 HKD. The company recently announced a Nasdaq at-the-market offering program of up to 200 million USD, which may pressure short-term sentiment. Financially, Q4 2025 revenue surged 126.79% YoY to 189.28 million HKD, but net loss expanded 19.9% YoY to -362.5 million HKD, with EPS at -0.978 HKD. Current price of 32.08 HKD is 66.36% below the 52-week high of 95.35 HKD, and trades below both the 20-day MA (35.94 HKD) and 60-day MA (36.27 HKD), with a YTD decline of 36.97%. However, the company has presented multiple clinical data updates at international conferences like EHA and ASCO recently.

Ascentage Pharma fell sharply in the afternoon session, closing down 5.05% at HK$35.32, matching an intraday low, as the market reacted to its plan to set up a US$200 million at-the-market (ATM) offering on Nasdaq via an SEC shelf filing, raising dilution concerns. Despite positive news flow, including updated clinical data from EHA2026 and ASCO 2026 for olverembatinib and lisaftoclax, and Q4 2025 revenue surging 126.79% YoY to HK$189 million, net loss widened to HK$363 million with EPS of -HK$0.978. The stock now trades below both its 20-day (HK$35.872) and 60-day (HK$37.21) moving averages, down 63% from its 52-week high of HK$95.35 and 30.61% YTD. Morgan Stanley, however, reiterated an 'Overweight' rating, lowering its target price to 89 yuan (from 89 yuan, the original did not specify a change).

Ascentage Pharma opened at HK$36.40 before tumbling to an intraday low of HK$34.52, eventually closing at HK$35.30, down 2.92% for the morning session. The decline was driven by the announcement of a US$200 million Nasdaq ATM offering program, raising concerns over near-term dilution. Despite positive clinical data for olverembatinib and lisaftoclax presented at EHA2026 and ASCO 2026, and Q4 2025 revenue surging 126.79% YoY to HK$189.3 million, the net loss widened 19.9% YoY to HK$362.5 million, with a net profit margin of -191.53%. The stock at HK$35.30 remains 62.98% below its 52-week high of HK$95.35 and below the 60-day MA of HK$37.67, though it has edged above the 20-day MA of HK$35.02, suggesting a tentative short-term floor.

Ascentage Pharma opened the morning session at 39.78 HKD and quickly dropped to 37.36 HKD within 10 minutes, a 5.0% decline from the previous close of 39.34 HKD. The selloff was driven by light volume (591,200 shares, turnover rate 0.16%), indicating limited supply but weak demand. Recent news flow includes multiple clinical data presentations at EHA2026, ASCO2026, and AACR2026 covering olverembatinib, lisaftoclax (APG-2575), and alrizomadlin (APG-115), yet these have not sparked price momentum. At 37.36 HKD, the stock is 60.82% below its 52-week high of 95.35 HKD, above its 20-day MA (34.728 HKD) but below the 60-day MA (38.183 HKD), showing a medium-term resistance. YTD decline stands at 26.6%, with a P/B of 9.52x and a negative P/E, reflecting ongoing losses. Morgan Stanley previously lowered the target price to 89 HKD? (data missing), while CICC maintains a Buy rating, signaling mixed institutional views.

Ascentage Pharma Group opened low in the morning session but surged rapidly, with the closing price at HKD 38.60, representing a 5.01% gain from the previous close of HKD 36.76. The rally was primarily driven by market optimism over clinical data for olverembatinib and lisaftoclax presented at the EHA2026 and ASCO 2026 congresses, while the recent grant of RSUs to 453 employees also signaled internal confidence. Financially, Q4 2025 operating revenue surged 126.79% YoY to HKD 189.28 million, but net loss widened to HKD 362.52 million, with EPS of -HKD 0.978. The stock hit an intraday high of HKD 38.60, reflecting a significant move from the opening of HKD 36.22, though it remains below its 52-week high. The PB ratio stands at 9.83x, typical for a high-growth biotech, while the PE ratio remains negative. However, the net profit margin stayed deeply negative, underscoring the company's ongoing investment phase before reaching profitability.